[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1: CIGB-66 (RBD 25 mcg + aluminum hydroxide 0.30 mg); 0.5 mL intramuscularly in the deltoid region (0-14-28 days schedule).Group 2: CIGB-66 (RBD 50 mcg + aluminum hydroxide 0.30 mg); 0.5 mL intramuscularly in the deltoid region (0-14-28 days schedule).Group 3: Placebo; 0.5 mL intramuscularly in the deltoid region (0-14-28 days schedule).Group 4: CIGB-66 (RBD 25 mcg + aluminum hydroxide 0.30 mg); 0.5 mL intramuscularly in the deltoid region (schedule 0-28-56 days).Group 5: CIGB-66 (RBD 50 mcg + aluminum hydroxide 0.30 mg); 0.5 mL intramuscularly in the deltoid region (schedule 0-28-56 days).Group 6: Placebo; 0.5 mL intramuscularly in the deltoid region (schedule 0-28-56 days).These interventions will be carried out during the first stage (phase I). Subsequently; an intermediate analysis will be carried out where doses and immunization schedules for phase II will be defined.;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Placebos;Injections; Intramuscular;CIGB-66", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "25 mcg + 0.30 mg;3 (day0-14-28)\n", "treatment_id": 1975, "treatment_name": "Cigb-66", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "50 mcg + 0.30 mg;3 (day0-14-28)\n", "treatment_id": 1975, "treatment_name": "Cigb-66", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "25 mcg + 0.30 mg;3 (day0-28-56)\n", "treatment_id": 1975, "treatment_name": "Cigb-66", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "50 mcg + 0.30 mg;3 (day0-28-56)\n", "treatment_id": 1975, "treatment_name": "Cigb-66", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1: CIGB-66 (RBD 25 mcg + aluminum hydroxide 0.30 mg); 0.5 mL intramuscularly in the deltoid region (0-14-28 days schedule). Group 2: CIGB-66 (RBD 50 mcg + aluminum hydroxide 0.30 mg); 0.5 mL intramuscularly in the deltoid region (0-14-28 days schedule). Group 3: Placebo; 0.5 mL intramuscularly in the deltoid region (0-14-28 days schedule). Group 4: CIGB-66 (RBD 25 mcg + aluminum hydroxide 0.30 mg); 0.5 mL intramuscularly in the deltoid region (schedule 0-28-56 days). Group 5: CIGB-66 (RBD 50 mcg + aluminum hydroxide 0.30 mg); 0.5 mL intramuscularly in the deltoid region (schedule 0-28-56 days). Group 6: Placebo; 0.5 mL intramuscularly in the deltoid region (schedule 0-28-56 days). These interventions will be carried out during the first stage (phase I). Subsequently; an intermediate analysis will be carried out where doses and immunization schedules for phase II will be defined.;Immunogenicity; Vaccine;CIGB-66", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]